Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
Trial ID or NCT#
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToShirely Paulose
Go Back To The Trial